文献速递肾小球疾病肾移植

基于iPSC来源足细胞的特发性肾病综合征个体化复发建模

Personalized disease recurrence modeling using iPSC-derived podocytes in patients with idiopathic nephrotic syndrome.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该研究利用5例患者及其活体供肾者的iPSC来源足细胞,检测患者血浆/血清诱导的足细胞损伤,发现F-actin重分布(FAR)能区分复发与未复发患者,且供者足细胞对相应患者样本的FAR反应与rFSGS发生相关,提示个体化评估rFSGS的可行性。

要点

  • FAR是唯一能稳定区分患者与健康供者样本的足细胞损伤检测指标。
  • rFSGS患者的供者足细胞暴露于对应患者样本时出现显著FAR,未复发者无此现象。
  • iPSC来源供者足细胞体外实验或可个体化评估rFSGS风险。

核心结论

  • 利用iPSC来源供者足细胞的体外实验可能实现rFSGS的个体化评估。

研究设计与样本

  • 纳入5例患者及其对应活体供肾者,其中3例发生rFSGS、2例未发生,1例患者(P5)携带NPHS2杂合突变。
  • 将外周血单核细胞重编程为iPSC并分化为足细胞,暴露于假定含CPF的患者血浆/血清。
  • 采用三种足细胞损伤检测:活性氧形成、细胞颗粒度诱导和F-actin重分布(FAR)定量评估。

主要发现

  • 成功分化为足细胞经形态学和蛋白表达确认。
  • 仅FAR能一致区分患者与健康供者样本。
  • 除P5外,所有移植前患者样本均引起对应患者足细胞显著FAR。
  • rFSGS患者的供者足细胞暴露于对应患者样本时出现显著FAR,未复发者无此现象。
  • FSGS患者样本对非对应供者足细胞的影响可变。

关键数值与推荐

  • rFSGS在肾移植后发生率为10%-50%。

临床怎么用

  • iPSC来源供者足细胞体外FAR检测或可用于移植前个体化评估rFSGS风险。

局限性

  • 样本量小(5例患者及对应供者),需更大 cohort 的前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary focal segmental glomerulosclerosis (FSGS) is characterized by podocyte injury and treatment-resistant nephrotic syndrome. Recurrence of the original disease after kidney transplantation (rFSGS) occurs in 10%-50% of patients. Unidentified circulating permeability factors (CPF) are likely involved in FSGS pathogenesis. We hypothesized that donor podocyte susceptibility to CPF is also relevant. We developed a personalized model for (r)FSGS using induced pluripotent stem cell (iPSC)-derived podocytes from patients and kidney donors. METHODS: Five patients and their respective living kidney donors were included. Three patients had developed rFSGS, and two patients manifested no symptoms of rFSGS. One patient (P5) had heterozygous mutations in NPHS2. Peripheral blood mononuclear cells were reprogrammed to iPSC, and differentiated to podocytes. iPSC-derived podocytes from either patients or donors were exposed to presumed CPF-containing plasma/serum of corresponding patients. Three assays to detect podocyte injury were performed: (i) reactive oxygen species formation, (ii) cellular granularity induction, and (iii) quantitative assessment of F-actin redistribution (FAR), a new quantitative method. Crossmatch experiments with donor iPSC-derived podocytes and patients samples assessed individual susceptibility to CPF-induced injury. RESULTS: Successful podocyte differentiation was confirmed by morphology and protein expression. Only FAR differentiated consistently between patient and healthy donor samples. All pre-transplant patient samples except P5 caused significant FAR in corresponding patient podocytes. Significant FAR was observed in donor podocytes exposed to corresponding patient samples in the setting of rFSGS, and not in donor podocytes exposed to samples of patients who did not develop rFSGS. Effects of FSGS patient samples on non-corresponding donor podocytes were variable. CONCLUSIONS: In vitro assays using iPSC-derived donor podocytes may allow individualized assessment of rFSGS. Prospective studies in a larger cohort are required to validate our findings.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. van den Berge BT, van den Broek M, Di Giovanni G, et al. Personalized disease recurrence modeling using iPSC-derived podocytes in patients with idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2025. PMID: 40036883. doi:10.1093/ndt/gfaf045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。